CL2017003006A1 - Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t - Google Patents

Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t

Info

Publication number
CL2017003006A1
CL2017003006A1 CL2017003006A CL2017003006A CL2017003006A1 CL 2017003006 A1 CL2017003006 A1 CL 2017003006A1 CL 2017003006 A CL2017003006 A CL 2017003006A CL 2017003006 A CL2017003006 A CL 2017003006A CL 2017003006 A1 CL2017003006 A1 CL 2017003006A1
Authority
CL
Chile
Prior art keywords
treatment
lymphocytes
methods
conditioning
conditioning patients
Prior art date
Application number
CL2017003006A
Other languages
English (en)
Inventor
Adrian Bot
Jeffrey S Wiezorek
William GO
Rajul JAIN
James N Kochenderfer
Steven A Rosenberg
Original Assignee
Kite Pharma Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc, Us Health filed Critical Kite Pharma Inc
Publication of CL2017003006A1 publication Critical patent/CL2017003006A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2053—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>LA INVENCIÓN PROPORCIONA MÉTODOS PARA INCREMENTAR LA EFICACIA DE UN TRATAMIENTO CON LINFOCITOS T EN UN PACIENTE EN NECESIDAD DE LOS MISMOS. LA INVENCIÓN INCLUYE UN MÉTODO PARA ACONDICIONAR UN PACIENTE ANTES DE UN TRATAMIENTO CON LINFOCITOS T, EN DONDE EL ACONDICIONAMIENTO INVOLUCRA ADMINISTRAR UNA COMBINACIÓN DE CICLOFOSFAMIDA Y FLUDARABINA.</p>
CL2017003006A 2015-05-28 2017-11-27 Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t CL2017003006A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562167750P 2015-05-28 2015-05-28
US201562262143P 2015-12-02 2015-12-02

Publications (1)

Publication Number Publication Date
CL2017003006A1 true CL2017003006A1 (es) 2018-05-11

Family

ID=57393284

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003006A CL2017003006A1 (es) 2015-05-28 2017-11-27 Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t

Country Status (19)

Country Link
US (5) US9855298B2 (es)
EP (2) EP3851110A1 (es)
JP (4) JP7197979B2 (es)
KR (5) KR102349677B1 (es)
CN (2) CN114344321A (es)
AU (3) AU2016268864B2 (es)
BR (1) BR112017025166A2 (es)
CA (1) CA2986798A1 (es)
CL (1) CL2017003006A1 (es)
DO (1) DOP2017000271A (es)
EA (1) EA201792649A1 (es)
HK (2) HK1246151A1 (es)
IL (7) IL295224B2 (es)
MA (2) MA55694A (es)
MX (4) MX2017015186A (es)
PH (1) PH12017502154A1 (es)
SG (2) SG10201913613SA (es)
TW (4) TWI868463B (es)
WO (1) WO2016191756A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11491187B2 (en) 2015-05-28 2022-11-08 Kite Pharma, Inc. Methods of conditioning patients for T cell therapy
US11779601B2 (en) 2015-05-28 2023-10-10 Kite Pharma, Inc. Diagnostic methods for T cell therapy

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
AU2012305931B2 (en) 2011-09-08 2017-09-07 Yeda Research And Development Co. Ltd Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
BR112017008042A2 (pt) 2014-10-20 2017-12-26 Juno Therapeutics Inc métodos e composições para dosagem em terapia de célula adotiva
JP7057748B2 (ja) 2015-07-16 2022-04-20 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 遺伝子改変された抗第三者中枢性メモリーｔ細胞および免疫療法におけるその使用
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
SMT202100564T1 (it) 2016-04-08 2022-01-10 Adaptimmune Ltd Recettori di cellule t
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
NZ749136A (en) 2016-05-25 2023-11-24 Council Queensland Inst Medical Res Methods of immunotherapy
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
CN110392736A (zh) * 2017-01-18 2019-10-29 耶达研究及发展有限公司 遗传修饰的反抑细胞及其在免疫治疗中的用途
BR112019014406A2 (pt) * 2017-01-20 2020-04-28 Atara Biotherapeutics Inc métodos de tratar esclerose múltipla usando células t autólogas
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
US12163952B2 (en) 2017-02-27 2024-12-10 Juno Therapeutics, Inc. Determining toxicity risk in CAR T-cell therapy
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EP3606518A4 (en) 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
EP3490605B1 (en) * 2017-04-01 2023-06-07 AVM Biotechnology, LLC Replacement of cytotoxic preconditioning before cellular immunotherapy
AU2018250148B2 (en) 2017-04-03 2021-09-23 Kite Pharma, Inc. Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
WO2018195339A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
TWI862477B (zh) 2017-05-26 2024-11-21 美商凱特製藥公司 製備和使用胚胎間充質先驅細胞的方法
AU2018275894B2 (en) * 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
WO2019060425A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology COMPOSITIONS FOR CHIMERIC ANTIGENIC RECEPTOR T CELL THERAPY AND USES THEREOF
IL273757B2 (en) 2017-10-02 2025-01-01 Gamida Cell Ltd Growing and using NK cell populations
EP3695408B1 (en) 2017-10-02 2026-01-21 The Broad Institute, Inc. Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
PE20211266A1 (es) 2017-10-31 2021-07-19 Allogene Therapeutics Inc Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
EP3706766A4 (en) 2017-11-09 2021-08-18 Sangamo Therapeutics, Inc. GENETIC MODIFICATION OF THE CYTOCINE INDUCTIBLE SH2-CONTAINING PROTEIN (CISH) GENE
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
US12116417B2 (en) 2017-11-14 2024-10-15 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
WO2019099707A1 (en) 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
CA3084446A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
BR112020014446A2 (pt) 2018-01-15 2020-12-29 Pfizer Inc. Métodos para administrar imunoterapia de receptor de antígeno quimérico em combinação com agonista de 4-1bb
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
SG11202007426XA (en) 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
CN111989344A (zh) * 2018-03-09 2020-11-24 科济生物医药（上海）有限公司 用于治疗肿瘤的方法和组合物
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
EP3735256A4 (en) 2018-03-22 2021-10-13 Windmil Therapeutics, Inc. BONE MARROW LYMPHOCYTES SPECIFIC TO PROSTATE CANCER AND ASSOCIATED USES
WO2019191752A1 (en) * 2018-03-30 2019-10-03 Ohio State Innovation Foundation Methods for pre-conditioning patients for t-cell therapy
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
KR20210008408A (ko) 2018-05-23 2021-01-21 싱가포르국립대학교 T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
KR102544086B1 (ko) 2018-06-01 2023-06-16 카이트 파마 인코포레이티드 키메라 항원 수용체 t 세포 요법
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US20210155941A1 (en) 2018-06-22 2021-05-27 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
CA3107383A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
CA3107378A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
EP3632446B3 (en) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Immunoablative therapies
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
KR20210113169A (ko) * 2018-11-01 2021-09-15 주노 쎄러퓨티크스 인코퍼레이티드 Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
KR102840400B1 (ko) 2018-12-12 2025-08-04 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
CA3125751A1 (en) * 2019-01-07 2020-07-16 Magenta Therapeutics, Inc. Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US20220142948A1 (en) 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
JP2022525928A (ja) * 2019-03-21 2022-05-20 ガミダ セル リミテッド 併用療法における移植に適したｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用
JP7654557B2 (ja) 2019-03-27 2025-04-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法
CN120172958A (zh) 2019-04-12 2025-06-20 C4医药公司 Ikaros和aiolos的三环降解物
US20200384027A1 (en) 2019-05-03 2020-12-10 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
CA3144871A1 (en) 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
IL292665B2 (en) * 2019-11-06 2026-02-01 Kite Pharma Inc Chimeric antigen receptor T cell therapy
CN112079934B (zh) * 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
JP2023513434A (ja) * 2020-01-24 2023-03-31 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法における投与ならびに濾胞性リンパ腫および辺縁帯リンパ腫の処置のための方法
AU2021217003A1 (en) 2020-02-04 2022-09-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-dinitrophenol chimeric antigen receptors
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US20210322471A1 (en) 2020-03-27 2021-10-21 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
CN116133679A (zh) 2020-06-30 2023-05-16 门德斯有限公司 白血病衍生细胞在卵巢癌疫苗中的用途
US20220155299A1 (en) 2020-10-28 2022-05-19 Kite Pharma, Inc. Flow cytometric method for characterization of t-cell impurities
WO2022097068A1 (en) 2020-11-05 2022-05-12 Dcprime B.V. Use of tumor-independent antigens in immunotherapies
WO2022150582A1 (en) 2021-01-10 2022-07-14 Kite Pharma, Inc. T cell therapy
AU2022211682A1 (en) 2021-01-22 2023-08-03 Mendus B.V. Methods of tumor vaccination
TW202241469A (zh) 2021-02-20 2022-11-01 美商凱特製藥公司 免疫療法
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
EP4337227A2 (en) * 2021-05-14 2024-03-20 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
US20250041339A1 (en) 2021-11-19 2025-02-06 The Trustees Of The University Of Pennsylvania Engineered Pan-Leukocyte Antigen CD45 to Facilityate CAR T Cell Therapy
US20230296610A1 (en) 2022-02-15 2023-09-21 Kite Pharma, Inc. Predicting adverse events from immunotherapy
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
KR20250097844A (ko) 2022-10-28 2025-06-30 카이트 파마 인코포레이티드 면역요법의 효능 향상 및 지속적인 반응
WO2024092227A1 (en) 2022-10-28 2024-05-02 Kite Pharma, Inc. Factors for optimizing immunotherapy
WO2024107891A2 (en) * 2022-11-16 2024-05-23 Nkarta, Inc. Dosing regimens for combination therapies
DE102022132084B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
DE102022132083B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
DE102022132082B4 (de) 2022-12-02 2024-08-08 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung.
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
KR20250158048A (ko) 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템
KR20250162836A (ko) 2023-03-17 2025-11-19 카이트 파마 인코포레이티드 종양 미세환경이 면역요법의 효능에 미치는 영향
WO2024211852A1 (en) * 2023-04-07 2024-10-10 Fate Therapeutics, Inc. Ipsc-derived nk cell for lymphoma treatment
WO2024243428A2 (en) * 2023-05-24 2024-11-28 Instil Bio Inc. Use of fusion constructs for cell therapy
EP4712987A2 (en) * 2023-06-27 2026-03-25 Nkarta, Inc. Methods for treatment using cd19-directed immunotherapies
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025096419A1 (en) 2023-10-31 2025-05-08 Lyell Immunopharma, Inc. T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof
WO2025096517A1 (en) 2023-11-01 2025-05-08 Kite Pharma, Inc. Factors for optimizing immunotherapy efficacy
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025188561A1 (en) 2024-03-04 2025-09-12 Kite Pharma, Inc. Predictive markers for immunotherapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US20030031652A1 (en) 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism
US7718196B2 (en) * 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
AU2003265948B8 (en) * 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
CA2794196A1 (en) 2010-03-23 2011-09-29 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
WO2013040557A2 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
EP3144008B1 (en) 2012-05-08 2018-01-17 The John Hopkins University Compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2014204762A1 (en) 2013-06-19 2014-12-24 Massachusetts Institute Of Technology In vivo targeting of cells with ligand-conjugated particles
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
MX2017012939A (es) * 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
MX388325B (es) 2015-05-28 2025-03-19 Kite Pharma Inc Metodos de diagnostico para tratamiento con linfocitos t.
IL295224B2 (en) * 2015-05-28 2025-07-01 Kite Pharma Inc Methods of conditioning patients for t cell therapy
PT3436079T (pt) * 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11491187B2 (en) 2015-05-28 2022-11-08 Kite Pharma, Inc. Methods of conditioning patients for T cell therapy
US11779601B2 (en) 2015-05-28 2023-10-10 Kite Pharma, Inc. Diagnostic methods for T cell therapy
US12458654B2 (en) 2015-05-28 2025-11-04 Kite Pharma Inc. Methods of conditioning patients for T cell therapy
US12559718B2 (en) 2015-05-28 2026-02-24 Kite Pharma, Inc. Diagnostic methods for t cell therapy

Also Published As

Publication number Publication date
TWI868463B (zh) 2025-01-01
US20230158075A1 (en) 2023-05-25
EA201792649A1 (ru) 2018-06-29
IL305621B1 (en) 2025-06-01
KR20250139881A (ko) 2025-09-23
BR112017025166A2 (en) 2018-07-31
US11491187B2 (en) 2022-11-08
IL284173A (en) 2021-07-29
IL312426A (en) 2024-06-01
MX2023000049A (es) 2023-02-01
JP7197979B2 (ja) 2022-12-28
MX2023000051A (es) 2023-02-01
US9855298B2 (en) 2018-01-02
MA43343A (fr) 2021-04-07
JP2021165291A (ja) 2021-10-14
KR20250136440A (ko) 2025-09-16
IL284173B1 (en) 2023-10-01
JP7238030B2 (ja) 2023-03-13
CN107921066A (zh) 2018-04-17
EP3302508A1 (en) 2018-04-11
EP3851110A1 (en) 2021-07-21
TW201717962A (zh) 2017-06-01
KR102349677B9 (ko) 2026-04-08
AU2022224754B2 (en) 2025-08-28
TW202419092A (zh) 2024-05-16
IL316196A (en) 2024-12-01
DOP2017000271A (es) 2018-02-15
MX2023000050A (es) 2023-02-01
CA2986798A1 (en) 2016-12-01
TWI803447B (zh) 2023-06-01
JP2023071823A (ja) 2023-05-23
US20250367221A1 (en) 2025-12-04
JP2018516915A (ja) 2018-06-28
IL284173B2 (en) 2024-02-01
AU2016268864B2 (en) 2022-06-02
IL312426B2 (en) 2026-02-01
KR20180011250A (ko) 2018-01-31
SG10201913613SA (en) 2020-03-30
AU2022224754A1 (en) 2022-09-22
IL305621B2 (en) 2025-10-01
US12458654B2 (en) 2025-11-04
AU2016268864A1 (en) 2017-12-07
KR20230147769A (ko) 2023-10-23
MA55694A (fr) 2022-02-23
US20170368101A1 (en) 2017-12-28
US20160346326A1 (en) 2016-12-01
IL295224A (en) 2022-10-01
EP3302508A4 (en) 2019-01-02
IL318826A (en) 2025-04-01
CN114344321A (zh) 2022-04-15
IL295224B1 (en) 2025-03-01
HK1246151A1 (zh) 2018-09-07
KR20220008388A (ko) 2022-01-20
WO2016191756A1 (en) 2016-12-01
IL255887B (en) 2022-09-01
SG10201913604TA (en) 2020-02-27
KR102349677B1 (ko) 2022-01-12
HK1248141A1 (zh) 2018-10-12
MX2017015186A (es) 2018-07-06
IL305621A (en) 2023-11-01
US10322146B2 (en) 2019-06-18
AU2025208570A1 (en) 2025-08-14
IL255887A (en) 2018-01-31
TW202517279A (zh) 2025-05-01
US20180369283A1 (en) 2018-12-27
PH12017502154A1 (en) 2018-05-28
JP2025148404A (ja) 2025-10-07
IL312426B1 (en) 2025-10-01
IL295224B2 (en) 2025-07-01
TW202319057A (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
CL2017003005A1 (es) Métodos de diagnóstico para tratamiento con linfocitos t
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
MX378273B (es) Compuestos activos hacia bromodominios.
PE20180260A1 (es) Metodos y kits para tratar la depresion
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
CL2016000354A1 (es) Modulación de la inmunidad tumoral
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
EA201790398A1 (ru) Способы лечения заболевания печени
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
MX2017009694A (es) Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l).
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
MX2015014713A (es) Uso de una composicion que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cancer.
MA40535A (fr) Imagerie et thérapie d&#39;une inflammation et d&#39;une infection ciblant hsp90
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
MX2020003049A (es) Semaglutida en la terapia medica.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
MX386374B (es) Composiciones farmacéuticas y alimenticias para inducir la saciedad y prolongar la saciedad en sujetos que lo necesiten.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX2017015424A (es) Nanoparticulas para su uso como vacuna terapeutica.